Ex­clu­sive: Hori­zon CEO Tim Wal­bert talks M&A, FTC post-Am­gen deal close

For 10 months, the bio­phar­ma in­dus­try wait­ed to see if Am­gen and Hori­zon Ther­a­peu­tics would pre­vail in their $27.8 bil­lion merg­er fol­low­ing scruti­ny and chal­lenges from the FTC and oth­er gov­ern­ment lead­ers.

Last Fri­day, the decades-old Cal­i­for­nia drug­mak­er closed its ac­qui­si­tion of the Dublin and Chica­go-area biotech, bring­ing a slate of rare dis­ease med­ica­tions in­to its port­fo­lio on the promise that Am­gen wouldn’t bun­dle its med­i­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER